Showing 541 - 560 results of 116,716 for search '(( a non decrease ) OR ( 5 ((step decrease) OR (((we decrease) OR (a decrease)))) ))', query time: 1.65s Refine Results
  1. 541
  2. 542

    The MMP was decreased by incubation with CytoD or LatB. by Dong-Hee Yang (566631)

    Published 2014
    “…An MMP collapse was detected as a decrease in the percentage of cells with high red fluorescence intensity. …”
  3. 543
  4. 544
  5. 545
  6. 546
  7. 547

    Functional characterization of the V9D and R10C substitutions in chicken ARF. by Doreen Schwochow Thalmann (3912649)

    Published 2017
    “…Spectra of all peptides in free form and at 25 μM concentration in complex with MDM2<sub>204-298</sub> are shown in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1006665#pgen.1006665.s008" target="_blank">S5 Fig</a>. …”
  8. 548
  9. 549

    Nur77 knockdown decreases cell viability and proliferation. by Alexa Tenga (2161780)

    Published 2016
    “…<p>(A) Daoy cells were transfected with 20 nM siNur77 or non-targeting control (NT), and cell viability was measured via the CellTiter-Glo assay every day for 3 days. …”
  10. 550
  11. 551
  12. 552
  13. 553

    Human preterm infants diagnosed with IUGR have decreased Paneth cell counts compared to preterm non-IUGR control infants. by Camille M. Fung (844334)

    Published 2016
    “…(A) IUGR infants had similar numbers of goblet cells per 100 epithelial cells compared to non-IUGR infants (p = 0.5). …”
  14. 554

    Decreased HIF levels associated with hyperoxic cell state. by Julie M. Koeman (108185)

    Published 2008
    “…<p>(A) Normalized densitometry of HIF-1α protein levels (•),HIF-1β protein levels (▴), and HIF-1 DNA-binding activity (⧫) as presented in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1000176#pgen-1000176-g005" target="_blank">Figure 5B</a> of the Jiang et al. article. …”
  15. 555
  16. 556
  17. 557
  18. 558

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  19. 559

    Intracameral injections of ATX inhibitor decreases IOP in rabbits. by Padma Iyer (141117)

    Published 2012
    “…Drug treated eyes showed a significant decrease in IOP from the baseline (by 6–7 mm Hg) at 24 and 48 hrs based on paired t-test. …”
  20. 560